Table 1.
Case | Reference | Age (years)/sex | Diagnosis | Donor source | Response |
---|---|---|---|---|---|
1 | Present report | 65/M | MPN | Haploidentical HSCT | CCyR |
2 | Konishi et al., 2018 [8] | 48/M | B-ALL/MPN | Mismatched unrelated, BM | CCyR |
3 | Montenegro et al., 2017 [3] | 41/F | B-ALL/MPN | NR | Residual disease |
4 | Wang et al., 2016 [9] | 56/F | B-ALL/MPN | Matched unrelated AHSCT | Remission for 5 months after AHSCT |
5 | Landberg et al., 2017 [10] | 21/M | MPN | Mismatched unrelated AHSCT | Remission for 4 years after AHSCT |
6 | Khodadoust et al., 2015 [11] | 47/M | Trilineage mixed-phenotype AL | Matched sibling allogeneic HSCT | Residual disease |
7 | Shimanuki et al., 2013 [12] | 58/F | AL with dysplasia | Matched sibling allogeneic HSCT | Residual disease and subsequent relapse |
8 | Morishige et al., 2013 [7] | 50/M | Trilineage AL/lymphoma | Cord blood | Remission for 2 years after AHSCT |
9 | Dolan et al., 2012 [6] | 8/M | MDS/MPN | Unrelated AHSCT | Remission for 4.5 years after AHSCT |
10 | Haslam et al., 2012 [13] | 21/M | B-ALL/MPN | Mismatched, unrelated AHSCT | Residual disease |
11 | Kim et al., 2011 [14] | 59/M | Myeloid, T cell | AHSCT | CCyR |
12 | Patnaik et al., 2010 [15] | 57/F | MPN | AHSCT | Remission for 42 months after AHSCT |
Abbreviations: M: male; F: female; MPN: myeloproiferative neoplasm; B-ALL: B-cell acute lymphoblastic leukaemia; CCyR: complete cytogenetic response; AL: acute leukaemia; MDS: myelodysplastic syndrome; AHSCT: allogeneic hematopoietic stem-cell transplantation; BM: bone marrow; NR: Not reported.